By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series
The What’s Next Longevity Innovation Summit, organized by Mary Furlong & Associates took place December 3-4, 2020, and hosted a panel highlighting how angel groups and family offices impact innovation within diseases affecting longevity. The panel revolved around how early-stage technology firms are developing and funding products aimed at well-known diseases that disproportionately affect aging Baby Boomers. These conditions range from arthritis, hearing and vision impairment, diabetes, cancer, mental health conditions, chronic respiratory diseases (CRDs), and central nervous system (CNS) diseases.
Angels and family offices want to participate in this market and provide alternative sources of early-stage capital to help launch these new technologies that will help find treatments for these ailments. There is a bevy of new age-tech products and services impacting the market and changing the landscape of aging. These two early-stage investor types are distinct from each other in many ways, but also work well together.
Learn how these investor types operate from prominent early-stage angels and family offices, as they discuss how private capital pools are working together to fund technology and products impacting longevity through healthcare innovation.
Want to join the conversation? Life Science Nation and Mary Furlong & Associates have teamed up to bring investors and early-stage companies working in the longevity market together for a virtual partnering event, January 14-15, 2021. There’s still time to sign up for Longevity, Health & Innovation and start meeting fundraising goals for the new year!
Next Phase Newsletter 
Leave a Reply